Is Alaunos Therapeutics, Inc. (TCRT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 13.5% / 30% | 0.1% / 30% | 1330.0% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 13.5% / 33% | 0.1% / 33% | 1330.0% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 39.6% / 33% | 0.2% / 33% | 1330.0% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 13.5% / 33% | 0.1% / 33% | 1330.0% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 39.6% / 33% | 0.2% / 50% | 1330.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -67883.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -145.6% | |
| Return on Assets (ROA) | -70.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Current Ratio | 2.9 |
| Total Assets | $3M |
Price & Trading
| Last Close | $3.01 |
| 50-Day MA | $2.98 |
| 200-Day MA | $3.10 |
| Avg Volume | 22K |
| Beta | -1.2 |
|
52-Week Range
$1.31
| |
About Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Alaunos Therapeutics, Inc. (TCRT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Alaunos Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Alaunos Therapeutics, Inc.'s debt ratio?
Alaunos Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Alaunos Therapeutics, Inc.'s key financial metrics?
Alaunos Therapeutics, Inc. has a market capitalization of $7M, and revenue of $10,000. Return on equity stands at -145.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.